New Bone-Boosting drug shows promise for osteoporosis
NCT ID NCT06577935
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests an experimental drug called AGA2118 in postmenopausal women aged 55 to 80 who have low bone density but no history of fractures. The goal is to see if the drug can safely increase bone mineral density over 12 months compared to a placebo. About 379 women will participate in this double-blind, dose-finding trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGA2118
What this could lead to
If successful, this could lead to a new treatment option that helps strengthen bones and reduce fracture risk in postmenopausal women with osteoporosis.
What could go wrong
This is an early Phase 2 dose-finding study, so it is not yet proven to work. The results may not lead to a final approved treatment, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635, United States
-
CE "Hospital #1" of Zhytomyr City Council
Kyiv, Ukraine, Ukraine
-
CIDIIM
Córdoba, Argentina
-
Center for Advanced Research & Education
Gainesville, Georgia, 30501, United States
-
Centro Médico Dra Laura Maffei e Investigación Cliínica Aplicada
Buenos Aires, Argentina, Argentina
-
Centro de Investigaciones Medicas Mar del Plata CIM
Mar del Plata, Argentina
-
Consultorio de Investigacion Clinica EMO SRL
Buenos Aires, Argentina, Argentina
-
Futuremeds Gdynia
Gdynia, 81-384, Poland
-
Futuremeds Lodz
Lodz, 91-363, Poland
-
Futuremeds Targowek
Warsaw, 03-291, Poland
-
Futuremeds Warszawa Centrum
Warsaw, 00-215, Poland
-
Futuremeds Wroclaw
Wroclaw, 53-673, Poland
-
IDIM
Buenos Aires, Argentina, Argentina
-
Instituto Médico Strusberg
Córdoba, Argentina, Argentina
-
Investigaciones Reumatologicas y Osteologicas SRL
Buenos Aires, Argentina, Argentina
-
Krakowskie Centrum Medyczne
Krakow, 31-501, Poland
-
Mautalen - Salud e Investigacion (Expertia S.A.)
Buenos Aires, Argentina, Argentina
-
Medical Center Universal Clinic "Oberig" of "Kapytal" LCC
Kyiv, Ukraine, Ukraine
-
NM Clinical Research & Osteoporosis Center, Inc.
Albuquerque, New Mexico, 87160, United States
-
PSSE Medical Centre Pulse
Vinnytsia, Ukraine, Ukraine
-
Puget Sound Osteoporosis Center
Burien, Washington, 98166, United States
-
Stat Research
Buenos Aires, Argentina, Argentina
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States